🇺🇸 FDA
Patent

US 9266928

Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction

granted A61KA61K2039/5258A61K2039/545

Quick answer

US patent 9266928 (Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2039/5258, A61K2039/545, A61K2039/55505, A61K2039/55561